Molecular Targets in Cancer Drug Discovery: Cell-Based Profiling

Authors: Weinstein, J.N.; Buolamwini, J.K.

Source: Current Drug Metabolism, Volume 6, Number 4, 1 March 2000 , pp. 473-483(11)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

The phrase molecular target-based drug discovery usually implies an in vitro biochemical assay or battery of assays. One portion of the U.S. National Cancer Institutes drug discovery program, to the contrary, examines molecular targets for cancer therapy in a cell-based format. That approach has a number of sig-nificant limitations, but it has produced databases of significant utility on the activities and structures of tested compounds, as well as on molecular characteristics of the cell types used for testing.

Keywords: cel based profiling; molecular target; cacer genome; NCI cell screen; anticancer agents; protein expression

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612003400894

Publication date: 2000-03-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.